Abstract 4006
Background
Short-course neoadjuvant radiotherapy of 5Gy × 5 fractions is recommended to be a standard treatment for the patients with ressectable stage II/III rectal cancer. While the effect of radiotherapy of 5Gy × 5f on the tumor microenvironment is still unclear. The purpose of this study was to evaluate the interactions between radiotherapy of 5Gy × 5f and the tumor immune microenvironment.
Methods
The changes in the number of immune cells, the changes of P-STAT1, P-STAT3, MICA, KIR, PD-L1 and Gal-1 in tumor before and after radiotherapy were assessed in mouse CT26 rectal cancer model. The effects of radiotherapy of 5Gy × 3f and 5Gy × 5f on HCT116, RKO, SW480,174T, DLD-1 cell lines were also investigated. Furthermore, clinical samples of patients with rectal cancer were analyzed. The changes of T lymphocytes in blood and T lymphocytes and NK cells in tumor before and after radiotherapy were tested. The infiltration of CD8 + T lymphocyte in tumor was studied as well.
Results
In CT26 models, the radiotherapy of 5Gy × 5f promoted CD4 + and CD8 + T lymphocyte infiltration (P
Conclusions
Radiotherapy of 5Gy × 5f could promote the infiltration of CD4 + and CD8 + T lymphocyte in local tumor, and enhance the anti-tumor effect of NK cells and T lymphocytes. Short-course neoadjuvant radiotherapy of 5Gy × 5f have immune stimulatory effects for rectal cancer.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
Chinese National Natural Science Foundation (NSFC 8120175).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract